DK1349944T3 - Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens - Google Patents

Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens

Info

Publication number
DK1349944T3
DK1349944T3 DK02729440T DK02729440T DK1349944T3 DK 1349944 T3 DK1349944 T3 DK 1349944T3 DK 02729440 T DK02729440 T DK 02729440T DK 02729440 T DK02729440 T DK 02729440T DK 1349944 T3 DK1349944 T3 DK 1349944T3
Authority
DK
Denmark
Prior art keywords
latency
pharmaceutically active
fusion protein
associated peptide
nucleic acid
Prior art date
Application number
DK02729440T
Other languages
English (en)
Inventor
Yuti Chernajovsky
Hanna Stina Dreja
Gillian Adams
Original Assignee
Queen Mary & Westfield College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary & Westfield College filed Critical Queen Mary & Westfield College
Application granted granted Critical
Publication of DK1349944T3 publication Critical patent/DK1349944T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02729440T 2001-01-09 2002-01-09 Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens DK1349944T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0100551.1A GB0100551D0 (en) 2001-01-09 2001-01-09 Protein
US09/756,283 US6942853B2 (en) 2001-01-09 2001-01-09 Latent fusion protein
PCT/GB2002/000068 WO2002055098A2 (en) 2001-01-09 2002-01-09 Latency associated peptide for providing latency to pharmaceutically active proteins

Publications (1)

Publication Number Publication Date
DK1349944T3 true DK1349944T3 (da) 2005-07-25

Family

ID=26245544

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02729440T DK1349944T3 (da) 2001-01-09 2002-01-09 Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens

Country Status (10)

Country Link
US (1) US6942853B2 (da)
EP (1) EP1349944B1 (da)
JP (1) JP4201253B2 (da)
AT (1) ATE293169T1 (da)
AU (1) AU2002219345B2 (da)
DE (1) DE60203692T2 (da)
DK (1) DK1349944T3 (da)
ES (1) ES2240740T3 (da)
GB (1) GB0100551D0 (da)
WO (1) WO2002055098A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
CN101044154A (zh) * 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
AU2006302587A1 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
DE102006009324A1 (de) 2006-03-01 2007-09-06 Dr.Ing.H.C. F. Porsche Ag Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
FR2932190A1 (fr) * 2008-06-10 2009-12-11 Commissariat Energie Atomique Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
WO2011123683A2 (en) * 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
EP2878308B1 (en) * 2013-12-02 2018-10-31 Thomas Harder Agents and methods for the suppression of T cell activation
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
WO2019222294A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
BR112021005907A2 (pt) 2018-09-27 2021-08-10 Xilio Development, Inc. citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
ES2780274A1 (es) * 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
KR20220101147A (ko) 2019-11-14 2022-07-19 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
EP4133085A1 (en) 2020-04-10 2023-02-15 CytomX Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4308594A2 (en) 2021-03-16 2024-01-24 CytomX Therapeutics, Inc. Masked activatable cytokine constructs and related compositions and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
CA2003886A1 (en) 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
ES2083469T3 (es) 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
KR100227406B1 (ko) 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 조성물
CA2712304C (en) 1994-06-10 2011-10-25 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
EP0977862B8 (en) * 1997-04-30 2009-09-16 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2004508838A (ja) * 2000-09-11 2004-03-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 組合せ蛍光エネルギー移動タグ及びそれらの使用

Also Published As

Publication number Publication date
US6942853B2 (en) 2005-09-13
US20020151478A1 (en) 2002-10-17
EP1349944B1 (en) 2005-04-13
DE60203692T2 (de) 2006-03-02
ATE293169T1 (de) 2005-04-15
GB0100551D0 (en) 2001-02-21
JP4201253B2 (ja) 2008-12-24
EP1349944A2 (en) 2003-10-08
AU2002219345B2 (en) 2006-03-16
JP2004520031A (ja) 2004-07-08
ES2240740T3 (es) 2005-10-16
WO2002055098A3 (en) 2002-11-21
DE60203692D1 (de) 2005-05-19
WO2002055098A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
WO2002008251A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
ATE500323T1 (de) Subtilisin-variante
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
WO2002008256A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
AUPR107800A0 (en) Peptide and nucleic acid molecule ii
AR008727A1 (es) COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO
MXPA03000627A (es) Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
WO2006090385A3 (en) Protease inhibitors and method of screening thereof
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
DE69941433D1 (de) Von protease typ ii spaltbares peptid
EP1613345A4 (en) COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
FR2828405B1 (fr) Vaccin anti-coronavirus
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
WO2002008257A3 (en) Siglec (sialic acid-binding ig-related lectin) polypeptides and uses thereof
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
DE60236330D1 (de) Biologisch aktive Peptide
HUP0300787A2 (hu) Új interferon a sclerosis multiplex kezelésére
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine